automated-news
One of the extraordinary things about the UK — a matter of no particular note to those born there, but startling to those who are not — is the postcode. The combination of letters and numbers that identifies a dozen or so adjacent addresses is far more granular than its equivalents elsewhere, and is
automated-news
The costs of remaining at the frontier of AI are punishing, but the penalties for falling behind may be even worse
automated-news
Even if he could do all he wants, it would be unlikely to solve the UK’s growth problem
automated-news
Everybody says the UK is a laughing stock. The economy is in the doldrums, the Royal Family has been besmirched by controversy and infighting and the country is about to have its seventh prime minister in 10 years. Britain, once a byword for political stability, has become an unserious country like
automated-news
Morning Bid: Samsung to serve chip taster for earnings feast Reuters
automated-news
Basel, July 6, 2026 - Novartis today announced that it has entered into an agreement to acquire Myricx Bio (“Myricx”), a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads.
automated-news
LONDON, July 06, 2026 (GLOBE NEWSWIRE) -- Myricx Bio, a UK-headquartered biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), today announced that it has reached agreement to be acquired by Novartis for up to $1.5 billion includi
automated-news
Genesis delivers binding A$5.6B "superior proposal" to merge with Vault Minerals
automated-news
MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis. The transaction is valued at up to US$1.5 bil
automated-news
PARIS & LONDON--(BUSINESS WIRE)--Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential mil